CN115770229A - Clopidogrel sulfate aspirin tablet and preparation method and application thereof - Google Patents
Clopidogrel sulfate aspirin tablet and preparation method and application thereof Download PDFInfo
- Publication number
- CN115770229A CN115770229A CN202211606681.7A CN202211606681A CN115770229A CN 115770229 A CN115770229 A CN 115770229A CN 202211606681 A CN202211606681 A CN 202211606681A CN 115770229 A CN115770229 A CN 115770229A
- Authority
- CN
- China
- Prior art keywords
- aspirin
- coating
- tablet
- clopidogrel
- sulfate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960001138 acetylsalicylic acid Drugs 0.000 title claims abstract description 283
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 title claims abstract description 281
- 229960003009 clopidogrel Drugs 0.000 title claims abstract description 205
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 239000010410 layer Substances 0.000 claims abstract description 143
- 239000011248 coating agent Substances 0.000 claims abstract description 122
- 238000000576 coating method Methods 0.000 claims abstract description 122
- 239000003814 drug Substances 0.000 claims abstract description 41
- 239000000843 powder Substances 0.000 claims abstract description 39
- 239000007888 film coating Substances 0.000 claims abstract description 27
- 238000009501 film coating Methods 0.000 claims abstract description 27
- 239000003826 tablet Substances 0.000 claims description 268
- FDEODCTUSIWGLK-RSAXXLAASA-N clopidogrel sulfate Chemical compound [H+].OS([O-])(=O)=O.C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl FDEODCTUSIWGLK-RSAXXLAASA-N 0.000 claims description 174
- 238000009505 enteric coating Methods 0.000 claims description 55
- 239000002702 enteric coating Substances 0.000 claims description 55
- 229950010477 clopidogrel hydrogen sulphate Drugs 0.000 claims description 52
- FDEODCTUSIWGLK-UHFFFAOYSA-N hydrogen sulfate;hydron;methyl 2-(2-chlorophenyl)-2-(6,7-dihydro-4h-thieno[3,2-c]pyridin-5-yl)acetate Chemical compound OS(O)(=O)=O.C1CC=2SC=CC=2CN1C(C(=O)OC)C1=CC=CC=C1Cl FDEODCTUSIWGLK-UHFFFAOYSA-N 0.000 claims description 51
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 50
- 238000002955 isolation Methods 0.000 claims description 47
- 239000006255 coating slurry Substances 0.000 claims description 45
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 39
- 239000011247 coating layer Substances 0.000 claims description 38
- 239000002202 Polyethylene glycol Substances 0.000 claims description 29
- 229920001223 polyethylene glycol Polymers 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 25
- 238000002156 mixing Methods 0.000 claims description 24
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 23
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 23
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 23
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 23
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 23
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 23
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 22
- 229920002472 Starch Polymers 0.000 claims description 21
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 21
- 235000019698 starch Nutrition 0.000 claims description 21
- 239000008107 starch Substances 0.000 claims description 21
- 239000001069 triethyl citrate Substances 0.000 claims description 21
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 21
- 235000013769 triethyl citrate Nutrition 0.000 claims description 21
- 239000002662 enteric coated tablet Substances 0.000 claims description 19
- 239000003085 diluting agent Substances 0.000 claims description 18
- 239000000463 material Substances 0.000 claims description 18
- 238000005507 spraying Methods 0.000 claims description 16
- 239000003963 antioxidant agent Substances 0.000 claims description 12
- 230000003078 antioxidant effect Effects 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 239000000853 adhesive Substances 0.000 claims description 10
- 230000001070 adhesive effect Effects 0.000 claims description 10
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 7
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 7
- 239000008101 lactose Substances 0.000 claims description 7
- 239000003605 opacifier Substances 0.000 claims description 6
- 239000000454 talc Substances 0.000 claims description 6
- 229910052623 talc Inorganic materials 0.000 claims description 6
- 230000004888 barrier function Effects 0.000 claims description 5
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 4
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 4
- 239000002002 slurry Substances 0.000 claims description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 238000012377 drug delivery Methods 0.000 claims 1
- 229960003958 clopidogrel bisulfate Drugs 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 6
- 230000009747 swallowing Effects 0.000 abstract description 4
- 210000003238 esophagus Anatomy 0.000 abstract description 2
- 235000019629 palatability Nutrition 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 description 48
- 239000000243 solution Substances 0.000 description 40
- 239000007787 solid Substances 0.000 description 33
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 30
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 24
- 239000002245 particle Substances 0.000 description 24
- 239000008213 purified water Substances 0.000 description 20
- 235000019441 ethanol Nutrition 0.000 description 16
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 14
- 229930003427 Vitamin E Natural products 0.000 description 12
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 12
- 239000004014 plasticizer Substances 0.000 description 12
- 229940046009 vitamin E Drugs 0.000 description 12
- 235000019165 vitamin E Nutrition 0.000 description 12
- 239000011709 vitamin E Substances 0.000 description 12
- 235000006708 antioxidants Nutrition 0.000 description 10
- 230000004584 weight gain Effects 0.000 description 10
- 235000019786 weight gain Nutrition 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 8
- 238000010008 shearing Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000013112 stability test Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- -1 aspirin clopidogrel hydrogen sulfate compound Chemical class 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920003139 Eudragit® L 100 Polymers 0.000 description 1
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940127217 antithrombotic drug Drugs 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000012055 enteric layer Substances 0.000 description 1
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012943 hotmelt Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229950005770 hyprolose Drugs 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000007909 melt granulation Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 238000013146 percutaneous coronary intervention Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a clopidogrel sulfate aspirin tablet, a preparation method and application thereof, and belongs to the technical field of medicines. The clopidogrel bisulfate aspirin tablet provided by the invention has the mass less than or equal to 0.35 g/tablet, solves the problem of difficulty in swallowing in clinical use by controlling the tablet weight, improves the clinical compliance, and utilizes the film coating layer, wherein the Opadry EZ coating powder can obviously improve the flowability of the tablet, greatly reduces the probability of throat or esophagus adhesion, is easier to swallow, and compared with other film coating systems, the friction force on the surface of the Opadry EZ coated tablet is obviously reduced once exposed to a humid condition, so that the better wet and slippery property is obtained, the clinical compliance is improved, the uncomfortable taste and smell are covered, the palatability of the tablet is improved, and the aesthetic feeling of the tablet is improved.
Description
Technical Field
The invention relates to the technical field of medicines, and in particular relates to a clopidogrel sulfate aspirin tablet as well as a preparation method and application thereof.
Background
The occurrence of cardiovascular and cerebrovascular diseases seriously jeopardizes life health, wherein the mortality rate of thrombotic diseases is high, the morbidity of thrombotic diseases is increased year by year, and the further expansion of the population is promoted by the increasing aging of the increasingly serious population. Myocardial infarction is the disease with the highest fatality rate, cerebral infarction is the disease with the highest disability rate, and the occurrence of clinical malignant diseases has a direct relationship with thrombosis. Therefore, with the rising incidence rate, the demand of antithrombotic drugs is increasing, and the development speed of the antithrombotic market is very fast, which has become one of the hot fields of drug development in the world.
The clopidogrel aspirin tablet is a compound preparation and is used for the conversion treatment of the combined medication of clopidogrel and aspirin under the following conditions: non-ST elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients who are stented after percutaneous coronary intervention; is suitable for thrombolytic ST-segment elevation type acute myocardial infarction patients treated by medicaments. The clopidogrel hydrogen sulfate aspirin tablet contains 75mg of clopidogrel hydrogen sulfate (calculated by clopidogrel) and 100mg of aspirin, is an original product imported from original research, has a supporting quotient of Sanofi K.K., and does not have a domestic clopidogrel hydrogen sulfate aspirin tablet product at present.
Chinese patent CN112587495A discloses a compound tablet preparation of aspirin and clopidogrel hydrogen sulfate, which is prepared into film coated tablet by tabletting aspirin enteric coated tablet and clopidogrel hydrogen sulfate granule, wherein the aspirin enteric coated tablet is composed of tablet containing medicine, enteric coated layer coating and isolating layer coating from inside to outside, the mass of the compound tablet preparation of aspirin and clopidogrel hydrogen sulfate is more than 0.5 g/tablet. Chinese patent CN109288805A discloses a compound aspirin clopidogrel bisulfate core-coated tablet, which comprises the following components from inside to outside: (i) aspirin tablet cores; (ii) an enteric coating layer; (iii) a clopidogrel bisulfate layer; and (iv) a film coating layer, wherein the mass of the compound aspirin clopidogrel hydrogen sulfate tablet is 1.3-1.6 g/tablet. The aspirin clopidogrel hydrogen sulfate compound tablet prepared by the prior art has large mass and is difficult to swallow in clinical use.
Disclosure of Invention
In view of the above, the invention aims to provide a clopidogrel sulfate aspirin tablet, and a preparation method and application thereof.
In order to achieve the above object, the present invention provides the following technical solutions:
the invention provides a clopidogrel sulfate aspirin tablet which sequentially comprises an aspirin tablet core, an enteric coating layer, a first isolation coating layer, a clopidogrel sulfate upper medicine layer, a second isolation coating layer and a film coating layer from inside to outside, wherein the mass of the clopidogrel sulfate aspirin tablet is less than or equal to 0.35 g/tablet;
based on the mass percentage content of the clopidogrel hydrogen sulfate aspirin tablet of 100 percent,
the aspirin tablet comprises the following components: 25 to 50 percent of aspirin, 0.25 to 4.5 percent of microcrystalline cellulose and 0.25 to 2 percent of diluent;
the enteric coating layer comprises the following components: 2.5 to 6 percent of enteric coating powder, 0.25 to 1.2 percent of triethyl citrate and 1.25 to 4.8 percent of opacifier;
the composition of the first release coating layer comprises: 0.5 to 8 percent of high-substituted hydroxypropyl cellulose;
the clopidogrel sulfate medicine-applying layer comprises the following components: 19 to 38 percent of clopidogrel sulfate, 0.5 to 5 percent of adhesive, 0.05 to 2 percent of antioxidant, 0.02 to 1 percent of polyethylene glycol and 1 to 5 percent of disintegrating agent; the amount of clopidogrel sulfate is calculated as clopidogrel;
the composition of the second release coating layer comprises: 0.5 to 8 percent of high-substituted hydroxypropyl cellulose;
the film coating layer comprises the following components: 3 to 8 percent of Opadry EZ coating powder.
Preferably, the enteric coating powder comprises one or more of a copolymer of methacrylic acid and ethyl acrylate, a copolymer of methacrylic acid and methyl methacrylate, and a copolymer of methacrylic acid and methyl methacrylate.
Preferably, the opacifier comprises one or more of talc, calcium carbonate, calcium sulfate and iron oxide.
Preferably, the diluent comprises starch and/or lactose.
The invention also provides a preparation method of the clopidogrel sulfate aspirin tablet in the technical scheme, which comprises the following steps:
mixing the enteric coating powder, triethyl citrate, talcum powder and water to obtain an enteric coating layer component solution;
mixing clopidogrel sulfate, an adhesive, an antioxidant, polyethylene glycol, a disintegrating agent, a diluent and an alcohol solvent to obtain a medicinal solution;
mixing high-substituted hydroxypropyl cellulose and a plasticizer or high-substituted hydroxypropyl cellulose and water to obtain first isolation layer coating slurry;
mixing the high-substituted hydroxypropyl cellulose, the plasticizer, the talcum powder and the alcohol solution to obtain second isolation layer coating slurry;
mixing the Opadry EZ coating powder with water to obtain film coating layer slurry;
mixing aspirin, microcrystalline cellulose and a diluent, and tabletting to obtain an aspirin tablet;
performing enteric coating on the aspirin tablet by using the enteric coating layer component solution to obtain an aspirin enteric tablet;
coating the aspirin enteric-coated tablet by using the first isolating layer coating slurry to obtain an aspirin isolating enteric-coated tablet;
the aspirin isolation enteric-coated tablet is coated with the medicine coating solution to obtain clopidogrel hydrogen sulfate aspirin tablets;
carrying out second isolation layer coating on the clopidogrel hydrogen sulfate aspirin tablets by using the second isolation layer coating pulp, and then carrying out film layer coating by using the film coating layer coating pulp to obtain the clopidogrel hydrogen sulfate aspirin tablets;
the enteric coating, the first isolating layer coating, the medicine applying, the second isolating layer coating and the film layer coating are all carried out in a coating pan.
Preferably, the parameters of the first barrier layer coating include: the spraying speed is 60-120 g/min, the rotating speed of a coating pan is 3-8 rmin, and the material temperature is 28-35 ℃.
Preferably, the parameters of the enteric coating include: the spraying speed is 60-120 g/min, the coating pan rotating speed is 3-8 rmin, and the material temperature is 28-35 ℃.
Preferably, the technological parameters of the medicine application comprise: the spraying speed of the medicine solution is 60-260 g/min, the rotating speed of a coating pan is 3-12 r/min, and the material temperature is 25-45 ℃.
Preferably, the process parameters of the second barrier layer coating and the film layer coating include: the spraying speed is independently 60-120 g/min, the rotating speed of the coating pan is independently 3-8 r/min, and the material temperature is independently 25-50 ℃.
The invention also provides the application of the clopidogrel hydrogen sulfate aspirin tablet in the technical scheme or the clopidogrel hydrogen sulfate aspirin tablet prepared by the preparation method in the technical scheme in the preparation of drugs for treating cardiovascular and cerebrovascular diseases.
The invention provides a clopidogrel hydrogen sulfate aspirin tablet, which sequentially comprises an aspirin tablet core, an enteric coating layer, a first isolation coating layer, a clopidogrel hydrogen sulfate drug loading layer, a second isolation coating layer and a film coating layer from inside to outside, wherein the mass of the clopidogrel hydrogen sulfate aspirin tablet is less than or equal to 0.35 g/tablet; the clopidogrel sulfate aspirin tablet comprises the following components in percentage by mass of 100 percent: 25 to 40 percent of aspirin, 0.25 to 4.5 percent of microcrystalline cellulose and 0.25 to 2 percent of starch; the enteric coating layer comprises the following components: 2.5 to 6 percent of enteric coating powder, 0.25 to 1.2 percent of triethyl citrate and 1.25 to 4.8 percent of talcum powder; the composition of the first release coating layer comprises: 0.5 to 3 percent of high-substituted hydroxypropyl cellulose, 0.05 to 1.2 percent of talcum powder and 0.05 to 0.15 percent of plasticizer; the clopidogrel sulfate medicine feeding layer comprises the following components: 25 to 40 percent of clopidogrel sulfate, 0.5 to 5 percent of adhesive, 0.05 to 2 percent of antioxidant, 0.02 to 1 percent of polyethylene glycol, 1 to 5 percent of disintegrating agent and 2.5 to 5 percent of diluent; the amount of clopidogrel sulfate is calculated by clopidogrel; the composition of the second release coating layer comprises: 1 to 6 percent of high-substituted hydroxypropyl cellulose, 0.1 to 0.3 percent of plasticizer and 0.2 to 2.4 percent of talcum powder; the film coating layer comprises the following components: 3 to 8 percent of Opadry EZ coating powder.
Clopidogrel sulfate has high viscosity, and two problems need to be solved in the production of core-spun tablets in the prior art, namely, 1 st: sticking problem of clopidogrel sulfate; and 2, a step of: the problem of damage to aspirin tablets during clopidogrel sulfate compression is solved by enlarging the weight of the granules, and the clopidogrel sulfate layer is required to reach a certain thickness so as to protect the tablet core. In the invention, the tablet core damage and sticking phenomenon caused by pressing do not exist when the coating is adopted for medicine application, so the product quality can be maintained after the quality of the tablet is reduced. The clopidogrel hydrogen sulfate aspirin tablet has the mass less than or equal to 0.35 g/tablet, solves the problem of difficulty in swallowing in clinical use by controlling the tablet weight, improves the clinical compliance, and utilizes a film coating layer, wherein the Opadry EZ coating powder can obviously improve the flowability of the tablet, greatly reduces the probability of throat or esophagus adhesion and is easier to swallow.
The invention also provides a preparation method of the clopidogrel hydrogen sulfate aspirin tablet in the technical scheme, wherein the enteric coating, the first isolating layer coating, the medicine feeding, the second isolating layer coating and the film layer coating are carried out in a coating pan, and the coating pan is adopted to replace a core-spun tablet tabletting machine, so that the problems of high production cost and low efficiency are solved, and the bottleneck problem of restricting the domestic production of clopidogrel hydrogen sulfate aspirin tablets is solved; and clopidogrel sulfate only needs to be mixed and coated with the adhesive, the antioxidant, the polyethylene glycol, the diluent and the disintegrating agent, so that the hot-melt granulation process of clopidogrel is avoided, expensive auxiliary materials are avoided, the cost is reduced, the process is simple, and the production efficiency is greatly improved.
Drawings
Fig. 1 is a graph showing the results of comparison of dynamic friction of clopidogrel sulfate aspirin tablets obtained in comparative example 1, example 10 and example 11;
FIG. 2 is a clopidogrel dissolution curve of clopidogrel sulfate aspirin tablets and clopidogrel sulfate tablets obtained in example 1;
FIG. 3 is an aspirin dissolution curve of a clopidogrel sulfate aspirin tablet prepared in example 1 and an aspirin tablet;
fig. 4 is a clopidogrel dissolution curve of the clopidogrel sulfate aspirin tablet prepared in example 2 and a clopidogrel sulfate tablet;
FIG. 5 is an aspirin dissolution curve of a clopidogrel sulfate aspirin tablet prepared in example 2 and an aspirin tablet;
FIG. 6 is a clopidogrel dissolution curve of a clopidogrel sulfate aspirin tablet prepared in example 3 and a clopidogrel sulfate tablet;
fig. 7 is an aspirin dissolution curve of the clopidogrel sulfate aspirin tablet prepared in example 3 and an aspirin tablet;
fig. 8 is a clopidogrel dissolution curve of clopidogrel sulfate aspirin tablets and clopidogrel sulfate tablets obtained in example 4;
fig. 9 is an aspirin dissolution curve of the clopidogrel sulfate aspirin tablet prepared in example 4 and an aspirin tablet;
FIG. 10 is a clopidogrel dissolution curve of a clopidogrel sulfate aspirin tablet prepared in example 5 and a clopidogrel sulfate tablet;
fig. 11 is an aspirin dissolution curve of the clopidogrel sulfate aspirin tablet prepared in example 5 and an aspirin tablet;
fig. 12 is a clopidogrel dissolution curve of clopidogrel sulfate aspirin tablets and clopidogrel sulfate tablets obtained in example 6;
fig. 13 is an aspirin dissolution curve of the clopidogrel sulfate aspirin tablet prepared in example 6 and an aspirin tablet;
fig. 14 is a clopidogrel dissolution curve of clopidogrel sulfate aspirin tablets and clopidogrel sulfate tablets obtained in example 7;
fig. 15 is an aspirin dissolution curve of the clopidogrel sulfate aspirin tablet prepared in example 7 and an aspirin tablet;
FIG. 16 is a clopidogrel dissolution curve of a clopidogrel sulfate aspirin tablet prepared in example 8 and a clopidogrel sulfate tablet;
FIG. 17 is an aspirin dissolution curve of a clopidogrel sulfate aspirin tablet prepared in example 8 and an aspirin tablet;
FIG. 18 is a clopidogrel dissolution curve of a clopidogrel sulfate aspirin tablet prepared in example 9 and a clopidogrel sulfate tablet;
fig. 19 is an aspirin dissolution curve of the clopidogrel sulfate aspirin tablet prepared in example 9 and an aspirin tablet;
fig. 20 is a clopidogrel dissolution curve of clopidogrel sulfate aspirin tablets and clopidogrel sulfate tablets obtained in example 10;
fig. 21 is an aspirin dissolution curve of the clopidogrel sulfate aspirin tablet prepared in example 10 and an aspirin tablet.
Detailed Description
The invention provides a clopidogrel hydrogen sulfate aspirin tablet, which sequentially comprises an aspirin tablet core, an enteric coating layer, a first isolation coating layer, a clopidogrel hydrogen sulfate drug loading layer, a second isolation coating layer and a film coating layer from inside to outside, wherein the mass of the clopidogrel hydrogen sulfate aspirin tablet is less than or equal to 0.35 g/tablet;
based on the mass percentage content of the clopidogrel hydrogen sulfate aspirin tablet as 100 percent,
the aspirin tablet comprises the following components: 25 to 40 percent of aspirin, 0.25 to 4.5 percent of microcrystalline cellulose and 0.25 to 2 percent of starch;
the composition of the enteric coating layer comprises: 2.5 to 6 percent of enteric coating powder, 0.25 to 1.2 percent of triethyl citrate and 1.25 to 4.8 percent of talcum powder;
the composition of the first release coating layer comprises: 0.5 to 3 percent of high-substituted hydroxypropyl cellulose, 0.05 to 1.2 percent of talcum powder and 0.05 to 0.15 percent of plasticizer;
the clopidogrel sulfate medicine feeding layer comprises the following components: 25 to 40 percent of clopidogrel sulfate, 0.5 to 5 percent of adhesive, 0.05 to 2 percent of antioxidant, 0.02 to 1 percent of polyethylene glycol, 1 to 5 percent of disintegrating agent and 2.5 to 5 percent of diluent; the amount of clopidogrel sulfate is calculated by clopidogrel;
the composition of the second release coating layer comprises: 1 to 6 percent of high-substituted hydroxypropyl cellulose, 0.1 to 0.3 percent of plasticizer and 0.2 to 2.4 percent of talcum powder;
the film coating layer comprises the following components: 3-8% of Opadry EZ coating powder.
In the present invention, all the raw material components are commercially available products well known to those skilled in the art unless otherwise specified.
In the present invention, the particle diameter of the raw material component is independently preferably 5 to 30 μm.
In the invention, the mass of the clopidogrel sulfate aspirin tablet is preferably 0.24-0.35 g/tablet, more preferably 0.25-0.32 g/tablet, even more preferably 0.25-0.30 g/tablet, and most preferably 0.26-0.30 g/tablet.
The clopidogrel sulfate aspirin tablet comprises the following components in percentage by mass: 25 to 40 percent of aspirin, preferably 30 to 40 percent, and more preferably 35 to 48 percent; microcrystalline cellulose 0.25 to 4.5%, preferably 0.5 to 4%, more preferably 1 to 3%; the diluent is 0.25 to 2%, preferably 0.5 to 1.5%, more preferably 1 to 1.5%.
In the present invention, the ratio of the particle size of aspirin in the range of 20 to 60 mesh is preferably not less than 70%, more preferably not less than 80%.
In the present invention, the microcrystalline cellulose preferably comprises microcrystalline cellulose KG802 and/or microcrystalline cellulose pH102.
The clopidogrel hydrogen sulfate aspirin tablet provided by the invention comprises an enteric coating layer in percentage by mass: 2.5 to 6 percent of enteric coating powder, preferably 3 to 5.5 percent, and more preferably 3.5 to 5 percent; triethyl citrate 0.25-1.2%, preferably 0.5-1%, more preferably 0.6-0.8%; 1.25 to 4.8%, preferably 1.5 to 4.5%, more preferably 2 to 4%, and still more preferably 2.5 to 3.5% of talc.
In the present invention, the enteric coating powder is preferably eudragit enteric coating powder, more preferably includes at least one of a copolymer of methacrylic acid and ethyl acrylate, a copolymer of methacrylic acid and methyl methacrylate, and further preferably one or more of a copolymer of methacrylic acid and ethyl acrylate (mass ratio 1. In a particular embodiment of the invention, the enteric coating powder is preferably ewt chi L30D-55 or ewt chi L100.
In the present invention, the particle size of the talc is preferably 325 to 1000 mesh.
The first isolation coating layer comprises the following components in percentage by mass: 0.5-3% of high-substituted hydroxypropyl cellulose, preferably 1.0-2.0%, more preferably 1.25-1.75%, and the substitution degree of the high-substituted hydroxypropyl cellulose is preferably 53.4-77.5%.
In the present invention, the composition of the first isolation coating layer preferably further includes 0.05 to 1.2% by mass of talc, preferably 0.1 to 1.0% by mass, and more preferably 0.3 to 0.6% by mass.
In the present invention, the composition of the first isolating coating layer preferably further includes a plasticizer 0.05 to 0.15%, preferably 0.075 to 0.125%, and more preferably 0.075 to 0.1% by mass.
The clopidogrel sulfate aspirin tablet provided by the invention comprises the following components in percentage by mass: 25-40% of clopidogrel sulfate (calculated by clopidogrel), preferably 28-38% of clopidogrel sulfate, and further preferably 32-38% of clopidogrel sulfate; 0.5 to 5% of a binder, preferably 1 to 4.5%, more preferably 2 to 4%; 0.05 to 2 percent of antioxidant, preferably 0.1 to 1.8 percent, and more preferably 0.5 to 1.5 percent; 0.02 to 1 percent of polyethylene glycol, preferably 0.1 to 0.8 percent, and more preferably 0.3 to 0.5 percent; 1 to 5 percent of disintegrating agent, preferably 1.5 to 4.5 percent, and more preferably 2 to 4 percent; the diluent is 2.5 to 5%, preferably 3.0 to 4.5%, more preferably 3.0 to 4.0%.
In the present invention, the binder preferably comprises one or more of hypromellose, highly substituted hyprolose (H-HPC) and povidone.
In the present invention, the substitution degree of the highly substituted hydroxypropylcellulose is preferably 53.4% to 77.5%.
In the present invention, the antioxidant preferably includes one or more of vitamin E, sodium metabisulfite, sodium sulfite, and vitamin C.
In the present invention, the polyethylene glycol preferably includes polyethylene glycol 4000 and/or polyethylene glycol 6000.
In the invention, the disintegrating agent is preferably low-substituted hydroxypropyl cellulose (L-HPC), and the substitution degree of the low-substituted hydroxypropyl cellulose is preferably 7-16%.
In the present invention, the diluent preferably includes starch and/or lactose. When the diluent is preferably a mixture of starch and lactose, the mass ratio of starch to lactose in the mixture is not particularly limited, and any ratio of the mixture may be used.
The clopidogrel hydrogen sulfate aspirin tablet provided by the invention comprises the following components in percentage by mass: 1 to 6 percent of high-substituted hydroxypropyl cellulose (H-HPC), preferably 1 to 5 percent, and more preferably 1 to 4 percent.
In the present invention, the substitution degree of the highly substituted hydroxypropylcellulose is preferably 53.4% to 77.5%.
In the present invention, the composition of the second isolation coating layer preferably further includes 0.1 to 0.3% by mass of a plasticizer, preferably 0.15 to 0.25% by mass, and more preferably 0.16 to 0.20% by mass.
In the present invention, the composition of the second isolation coating layer preferably further includes 0.2 to 2.4% by mass of talc, preferably 0.2 to 2.0% by mass, and more preferably 0.5 to 1.5% by mass.
The clopidogrel hydrogen sulfate aspirin tablet comprises the following film coating layers in percentage by mass: the Opadry EZ coating powder is 3-8%, preferably 3-6%, more preferably 3-5%.
The invention provides a preparation method of clopidogrel hydrogen sulfate aspirin tablets in the technical scheme, which comprises the following steps:
mixing the enteric coating powder, triethyl citrate, talcum powder and water to obtain an enteric coating layer component solution;
mixing clopidogrel sulfate, an adhesive, an antioxidant, polyethylene glycol, a disintegrating agent, a diluent and an alcohol solvent to obtain a medicinal solution;
mixing high-substituted hydroxypropyl cellulose, a plasticizer, talcum powder and water to obtain first isolation layer coating slurry;
mixing the high-substituted hydroxypropyl cellulose, the plasticizer, the talcum powder and the alcohol solvent to obtain second isolating layer coating slurry;
mixing the Opadry EZ coating powder with water to obtain film coating layer slurry;
mixing aspirin, microcrystalline cellulose and a diluent, and tabletting to obtain an aspirin tablet;
performing enteric coating on the aspirin tablet by using the enteric coating layer component solution to obtain an aspirin enteric tablet;
coating the aspirin enteric-coated tablet by using the first isolating layer coating slurry to obtain an aspirin isolating enteric-coated tablet;
the aspirin isolation enteric-coated tablet is coated with the medicine coating solution to obtain clopidogrel hydrogen sulfate aspirin tablets;
carrying out second isolation layer coating on the clopidogrel hydrogen sulfate aspirin tablets by using the second isolation layer coating pulp, and then carrying out film layer coating by using the film coating layer coating pulp to obtain the clopidogrel hydrogen sulfate aspirin tablets;
the enteric coating, the first isolating layer coating, the medicine applying, the second isolating layer coating and the film layer coating are all carried out in a coating pan.
The invention mixes the enteric coating powder, triethyl citrate, talcum powder and water to obtain the component solution of the enteric coating layer.
In the present invention, the mixing is preferably: dissolving the triethyl citrate into water, adding an opacifier for shearing, and adding the enteric coating powder under the stirring condition.
The dissolving, shearing and stirring conditions are not particularly limited in the present invention and may be in a manner well known to those skilled in the art.
The clopidogrel sulfate, the adhesive, the antioxidant, the polyethylene glycol, the disintegrating agent, the diluent and the alcohol solvent are mixed to obtain the medicinal solution, and the mixing mode is not particularly limited in the invention, and the mixing mode can be realized by adopting a mode which is well known to a person skilled in the art, such as shearing, and in the embodiment of the invention, the high-speed shearing at 1000 revolutions per minute is preferably carried out for 5 minutes.
The high-substituted hydroxypropyl cellulose, the plasticizer, the talcum powder and the water are mixed to obtain the first isolating layer coating slurry.
In the present invention, the enteric coating syrup preferably has a mass concentration of 15 to 25%, preferably 18 to 22%.
In the present invention, the mass concentration of the first separator slurry is preferably 2 to 8%, more preferably 3 to 7%.
The concentration of the clopidogrel sulfate medicine-applying layer is controlled to be 15-35%, preferably 20-30%, and the particle size of the clopidogrel sulfate is controlled to be 5-30 μm, preferably 10-20 μm.
The method comprises the steps of mixing high-substituted hydroxypropyl cellulose, a plasticizer, talcum powder and an alcohol solvent to obtain second isolating layer coating pulp, wherein the mass concentration of the second isolating layer coating pulp is preferably 2-8%, and is preferably 3-6%.
The invention is not particularly limited in the specific kind of the alcohol solvent, and the alcohol solvent known to those skilled in the art, such as ethanol, can be used.
The invention mixes the Opadry EZ coating powder with water to obtain the film layer coating slurry.
In the present invention, the mass concentration of the film layer coating syrup is preferably 8 to 25%, more preferably 10 to 18%.
The aspirin, the microcrystalline cellulose and the diluent are mixed and tabletted to obtain the aspirin tablet.
In the present invention, the pressure of the tablet is preferably 12 to 20KN.
In the present invention, the pellet is preferably a straight pellet using a punch of 7mm in diameter.
The aspirin enteric-coated tablet is obtained by carrying out enteric coating on the aspirin tablet by using the enteric coating layer component solution.
In the present invention, the parameters of the enteric coating preferably include: the spraying speed is 60-120 g/min, the rotating speed of a coating pan is 3-8 rmin, and the material temperature is 28-35 ℃.
In the present invention, the weight of the enteric coating is preferably increased by 12 to 20%, more preferably 14 to 18%.
In the invention, the tablet weight of the aspirin enteric-coated tablet is preferably 125-140 mg.
The aspirin enteric-coated tablet is coated by the first isolating layer coating slurry through the first isolating layer to obtain the aspirin isolating enteric-coated tablet.
In the present invention, the parameters for coating the first separation layer preferably include: the spraying speed is 60-120 g/min, the coating pan rotating speed is 3-8 rmin, and the material temperature is 28-35 ℃.
In the present invention, the weight of the first isolation layer coating is preferably increased by 2 to 4%, more preferably 2 to 3%.
The clopidogrel hydrogen sulfate aspirin tablet is prepared by using the medicine feeding solution to feed the aspirin isolated enteric-coated tablet.
In the present invention, the parameters for administration preferably include: the spraying speed is 60-260 g/min, the rotating speed of a coating pan is 3-12 r/min, and the material temperature is 25-45 ℃.
In the invention, the weight of the medicine is increased by 75-140%, and the weight is increased by 80-120%.
The clopidogrel hydrogen sulfate aspirin tablet is coated with a second isolation layer by using the second isolation layer coating slurry, and then is coated with a film layer by using the film layer coating slurry to obtain the clopidogrel hydrogen sulfate aspirin tablet.
In the present invention, the parameters of the second barrier layer coating and the film layer coating preferably include: the spraying speed is independently 60-120 g/min, the rotating speed of the coating pan is independently 3-8 r/min, and the material temperature is independently 30-50 ℃.
In the present invention, the weight of the second isolation layer coating is preferably increased by 2 to 5%, more preferably 2 to 4%.
In the present invention, the weight of the film layer coating is preferably increased by 2 to 7%, more preferably 3 to 5%.
After the coating of the film layer is finished, the invention preferably further comprises the step of packaging by adopting aluminum and plastic.
In the invention, the invention also provides the application of the clopidogrel sulfate aspirin tablet in the technical scheme or the clopidogrel sulfate aspirin tablet prepared by the preparation method in the technical scheme in the preparation of medicaments for treating cardiovascular and cerebrovascular diseases.
The invention is not particularly limited to the specific manner of use described, as such may be readily adapted by those skilled in the art.
The technical solution of the present invention will be clearly and completely described below with reference to the embodiments of the present invention. It should be apparent that the described embodiments are only some embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
(1) The clopidogrel sulfate aspirin tablet comprises the following components:
the aspirin tablet comprises the following components: 100mg of aspirin (the ratio of the particle size of 20-60 meshes is 80%), 5mg of starch and 10215mg of microcrystalline cellulose;
the enteric coating comprises the following components: triethyl citrate 0.4mg, talcum powder 5mg, purified water 50mg, eudragit L30D-5540mg;
the first isolating layer coating slurry comprises the following components: 3wt% of an aqueous solution of H-HPC;
the composition of the medicine solution is as follows: 4.5mg of adhesive H-HPC (the purchasing manufacturer is Shenzhen Yoypu medicine, inc.), 5mg of disintegrant L-HPC (the purchasing manufacturer is Shenzhen Yoypu medicine, inc.), 1mg of antioxidant vitamin E, 4mg of polyethylene glycol, 98.0mg of clopidogrel sulfate, 95% ethanol solution (abbreviated as 95% ethanol) in volume fraction, 25wt% of solid content and weight increment after loading;
the second isolating layer coating slurry comprises the following components: H-HPC, polyethylene glycol and 95% ethanol, the solid content is 3wt%;
coating slurry on the film layer: opadry EZ coating powder (model number is Opadry EZ color, and purchasing manufacturer is Shanghai Kalekang coating technology Co., ltd.) and purified water, and the solid content is 20wt%.
(2) The preparation method of the clopidogrel sulfate aspirin tablet comprises the following steps:
(2.1) uniformly mixing aspirin, starch and microcrystalline cellulose, directly tabletting by using a punch with the diameter of 7mm, and pressing under the pressure of 12kN to obtain the aspirin tablet.
(2.2) enteric coating: dissolving triethyl citrate in purified water, adding pulvis Talci, high-shearing at 1000r/min for 5min, adding Eudragit L30D-55 under slowly stirring (200 r/min), and mixing to obtain enteric coating solution; coating the aspirin tablets by using the enteric-coated coating solution at a coating speed of 60g/min, a rotating speed of the coating pan of 3r/min and a material temperature of 28 ℃ by using a coating pan to obtain the aspirin enteric-coated tablets (the tablet weight is 141 mg/tablet, and the weight is increased by 14.9 percent relative to the aspirin tablets).
(2.3) coating of the first separation layer: spraying at a speed of 60g/min, rotating at a speed of 3 revolutions per minute in a coating pan, heating the material at 28 ℃, and coating (the tablet weight is 145.2mg, and the weight is increased by 2.97%);
(2.4) medicine application: dissolving the agents H-HPC, L-HPC, vitamin E and polyethylene glycol in 95% ethanol, adding micronized clopidogrel sulfate (particle size is 5-30 μm), and high-shearing at the speed of 1000r/min for 5min to obtain a medicine solution; and coating the aspirin enteric-coated tablet by using the medicinal solution at the spraying speed of 60g/min, the rotating speed of a coating pot of 3r/min and the material temperature of 25 ℃ to obtain the clopidogrel hydrogen sulfate aspirin tablets (the weight of the tablets is 257.7mg, and the weight is increased by 77.5 percent relative to the aspirin enteric-coated tablet).
(2.5) coating of the second separation layer: coating the clopidogrel aspirin sulfate tablet by using the isolating layer coating slurry at the spraying speed of 120g/min, the rotating speed of a coating pan of 3r/min and the material temperature of 25 ℃ to obtain the clopidogrel aspirin sulfate tablet containing an isolating layer (the weight is increased by 3 percent relative to the clopidogrel aspirin sulfate tablet).
(2.6) film coating: coating the clopidogrel aspirin tablet containing the isolation coating layer by using the film layer coating slurry at a spraying speed of 60g/min, a coating pot rotating speed of 3r/min and a material temperature of 25 ℃, and carrying out aluminum-plastic packaging on the obtained clopidogrel aspirin tablet (the tablet weight is 0.278 g/tablet, and the weight is increased by 4.7 percent relative to the clopidogrel aspirin tablet containing the isolation coating layer).
Example 2
Clopidogrel sulfate aspirin tablets were prepared according to the method of example 1, differing from example 1 only in that:
the aspirin tablet comprises the following components: 100mg of aspirin (the ratio of the particle size of 20-60 meshes is 80%), 6mg of starch and 1029mg of microcrystalline cellulose;
the enteric coating comprises the following components: 0.4mg of triethyl citrate, 7mg of talcum powder, 50mg of purified water and 30D-5540mg of Equidz L, wherein the weight is increased by 16%;
the first isolating layer coating slurry comprises the following components: 5% by weight of an aqueous H-HPC solution, increased by 3%;
the composition of the medicine solution is as follows: 5mg of H-HPC, 5mg of L-HPC, 2mg of vitamin E, 5.8mg of polyethylene glycol, 98.0mg of micronized clopidogrel sulfate (particle size is 5-30 mu m), and absolute ethyl alcohol with the solid content of 28wt%;
the second isolating layer coating slurry comprises the following components: H-HPC and 95% ethanol, the solid content is 3wt%, and the weight is increased by 3%;
coating slurry on the film layer: opadry EZ coating powder and purified water, wherein the solid content is 18wt%;
obtaining clopidogrel sulfate aspirin tablets (the weight of the tablet is 0.273 g/tablet, and the weight of the tablet is increased by 5 percent compared with that of the clopidogrel sulfate aspirin tablet containing a second isolation coating layer)
Example 3
Clopidogrel sulfate aspirin tablets were prepared according to the method of example 1, differing from example 1 only in that:
the aspirin tablet comprises the following components: 100mg of aspirin (80% of particle size of 20-60 meshes), 8mg of starch and 102-10 mg of microcrystalline cellulose;
the enteric-coated layer coating liquid comprises: 0.8mg of triethyl citrate, 9mg of talcum powder, 50mg of purified water, 100 40mg of Ewing L, 20 percent of solid content and 16 percent of weight gain;
the first isolating layer coating slurry comprises the following components: 4mg of H-HPC and 40001mg of polyethylene glycol are prepared into 5wt% aqueous solution, and the weight is increased by 3.4%;
the composition of the medicine solution is as follows: 6mg of H-HPC, 7.5mg of L-HPC, 0.25mg of vitamin E, 8mg of polyethylene glycol, 98.0mg of micronized clopidogrel sulfate (particle size is 5-30 mu m), 95% volume fraction ethanol solution (abbreviated as 95% ethanol), and 26wt% solid content;
the second isolating layer coating slurry comprises the following components: H-HPC2.7mg, talcum powder 2.7mg and absolute ethyl alcohol, the solid content is 3wt%;
coating slurry on the film layer: opadry EZ coating powder (the model is Opadry EZ color, and the purchasing manufacturer is Shanghai Kalekang coating technology limited) and purified water, wherein the solid content is 18wt%;
the clopidogrel hydrogen sulfate aspirin tablet containing the second isolation coating layer is increased by 3 percent relative to the clopidogrel hydrogen sulfate aspirin tablet;
the tablet weight of the clopidogrel sulfate aspirin tablet is 0.276 g/tablet, and is 3 percent of the weight of the clopidogrel sulfate aspirin tablet containing the second isolation coating layer.
Example 4
Clopidogrel sulfate aspirin tablets were prepared according to the method of example 1, differing from example 1 only in that:
the aspirin tablet comprises the following components: 100mg of aspirin (the ratio of the particle size of 20-60 meshes is 80%), 7mg of starch and 8028mg of microcrystalline cellulose KG;
the enteric coating comprises the following components: triethyl citrate 0.6mg, talcum powder 8mg, purified water 50mg, eudragit L100 40mg, weight gain 16%;
the first isolating layer coating slurry comprises the following components: 4mg of H-HPC and 40001mg of polyethylene glycol are prepared into 5wt% aqueous solution, and the weight is increased by 2.4%;
the composition of the medicine solution is as follows: 5.5mg of H-HPC, 6mg of L-HPC, 0.2mg of vitamin E, 5.8mg of polyethylene glycol, 98.0mg of micronized clopidogrel sulfate (particle size is 5-30 mu m), and anhydrous ethanol with the solid content of 26wt%;
the second isolating layer coating slurry comprises the following components: 3mg of H-HPC, 2.5mg of talcum powder and absolute ethyl alcohol, wherein the solid content is 5wt%;
coating slurry on the film layer: opadry EZ coating powder (opadry EZ color, shanghai Kalerkang coating technology Co., ltd.) and purified water, the solid content is 18wt%;
the clopidogrel hydrogen sulfate aspirin tablet containing the second isolation coating layer is increased by 2.6 percent relative to the clopidogrel hydrogen sulfate aspirin tablet; the weight of the film coating is increased by 3 percent relative to the clopidogrel sulfate aspirin tablet containing the second isolation coating layer.
The tablet weight of the clopidogrel sulfate aspirin tablet is 0.27 g/tablet.
Example 5
Clopidogrel sulfate aspirin tablets were prepared according to the method of example 1, differing from example 1 only in that:
the aspirin tablet comprises the following components: 100mg of aspirin (the ratio of the particle size of 20-60 meshes is 80%), 7mg of starch and 802 mg of microcrystalline cellulose KG;
the enteric-coated layer coating liquid comprises: 0.8mg of triethyl citrate, 8mg of talcum powder, 50mg of purified water and 30D-5540mg of Equidz L, wherein the weight is increased by 14%;
the first isolating layer coating slurry comprises the following components: 5wt% of H-HPC aqueous solution, weight gain 3.2%;
the composition of the medicine solution is as follows: 5.0mg of H-HPC, 6mg of L-HPC, 0.18mg of vitamin E, 6000.0 mg of polyethylene glycol, 98.0mg of micronized clopidogrel sulfate, absolute ethyl alcohol and 25wt% of solid content; micronization treatment of clopidogrel sulfate is obtained by micronization treatment of clopidogrel sulfate, and the particle size is 5-30 mu m;
the second isolating layer coating slurry comprises the following components: H-HPC3.5mg, talcum powder 2mg and absolute ethyl alcohol, wherein the solid content is 4wt%;
coating slurry on the film layer: opadry EZ coating powder (type opadry EZ color, purchased from shanghai kalekang coating technology limited) and purified water, with a solid content of 20wt%.
The clopidogrel hydrogen sulfate aspirin tablet containing the second isolation coating layer is increased by 3.6 percent relative to the clopidogrel hydrogen sulfate aspirin tablet, and the film coating is increased by 5 percent relative to the clopidogrel hydrogen sulfate aspirin tablet containing the second isolation coating layer.
The tablet weight of the clopidogrel sulfate aspirin tablet is 0.272 g/tablet.
Example 6
Clopidogrel sulfate aspirin tablets were prepared according to the method of example 1, differing from example 1 only in that:
the aspirin tablet comprises the following components: 100mg of aspirin (the ratio of the particle size of 20-60 meshes is 80%), 7mg of starch and 1028mg of microcrystalline cellulose pH;
the enteric-coated layer coating liquid comprises: triethyl citrate 0.4mg, talcum powder 8mg, purified water 50mg, ewing L30D-5540mg, enteric layer weight gain 18%;
the first isolating layer coating slurry comprises the following components: 3wt% of an aqueous solution of H-HPC;
the composition of the medicine solution is as follows: 5.5mg of H-HPC, 5mg of starch, 6mg of L-HPC, 1.6mg of vitamin E, 6000.0 mg of polyethylene glycol and 98.0mg of micronized clopidogrel sulfate, and the solid content of absolute ethyl alcohol is 24wt%; micronization treatment of clopidogrel sulfate is obtained by micronization treatment of clopidogrel sulfate, and the particle size is 5-30 mu m;
the second isolating layer coating slurry comprises the following components: 3mg of H-HPC, 3mg of polyethylene glycol and absolute ethyl alcohol, wherein the solid content is 6wt%;
coating slurry on the film layer: opadry EZ coating powder (the model is Opadry EZ color, and the purchasing manufacturer is Shanghai Kalekang coating technology limited) and purified water, wherein the solid content is 20wt%;
the clopidogrel bisulfate aspirin tablet containing the second isolation coating layer is increased by 4 percent relative to the clopidogrel bisulfate aspirin tablet, and the film coating is increased by 5 percent relative to the clopidogrel bisulfate aspirin tablet containing the second isolation coating layer;
the tablet weight of the clopidogrel sulfate aspirin tablet is 0.285 g/tablet.
Example 7
Clopidogrel sulfate aspirin tablets were prepared according to the method of example 1, differing from example 1 only in that:
the aspirin tablet comprises the following components: 100mg of aspirin (the ratio of the particle size of 20-60 meshes is 80%), 7mg of starch and 102 mg of microcrystalline cellulose;
the enteric coating comprises the following components: triethyl citrate 1.2mg, talcum powder 8mg, purified water 50mg, ewing L30D-5540mg, weight gain 15%;
the first isolating layer coating slurry comprises the following components: H-HPC3wt% aqueous solution, 3.5% weight gain;
the composition of the medicine solution is as follows: 6.5mg of H-HPC, 6mg of starch, 0.18mg of vitamin E, 6000.0 mg of polyethylene glycol, 5.0mg of L-HPC, 98.0mg of micronized clopidogrel sulfate and absolute ethyl alcohol, wherein the solid content is 26wt%; micronization treatment of clopidogrel sulfate is obtained by micronization treatment of clopidogrel sulfate, and the particle size is 5-30 mu m;
the second isolating layer coating slurry comprises the following components: H-HPC2.7mg, polyethylene glycol 60002.7mg and absolute ethanol, the solid content is 5wt%;
coating slurry on the film layer: opadry EZ coating powder (model number is Opadry EZ color, and purchasing manufacturer is Shanghai Kalekang coating technology Co., ltd.) and purified water, and the solid content is 18wt%.
The clopidogrel hydrogen sulfate aspirin tablet containing the second isolation coating layer is increased by 3 percent relative to the clopidogrel hydrogen sulfate aspirin tablet, and the film coating is increased by 5 percent relative to the clopidogrel hydrogen sulfate aspirin tablet containing the second isolation coating layer;
the tablet weight of the clopidogrel sulfate aspirin tablet is 0.279g per tablet.
Example 8
Clopidogrel sulfate aspirin tablets were prepared according to the method of example 1, differing from example 1 only in that:
the aspirin tablet comprises the following components: 100mg of aspirin (the proportion of the particle size of 20-60 meshes is 80%), 7mg of starch and 102 mg of microcrystalline cellulose pH;
the enteric coating comprises the following components: triethyl citrate 1.4mg, talcum powder 8mg, purified water 50mg, ewing L30D-5540mg, weight gain 16.2%;
the first isolating layer coating slurry comprises the following components: 3wt% of an aqueous solution of H-HPC, increased by 2.2%;
the composition of the medicine solution is as follows: 5.5mg of H-HPC, 5mg of lactose, 6mg of L-HPC, 0.2mg of vitamin E, 6000.8mg of polyethylene glycol, 98.0mg of clopidogrel sulfate subjected to micronization treatment, absolute ethyl alcohol and the solid content of 26wt%; micronization treatment of clopidogrel sulfate is obtained by micronization treatment of clopidogrel sulfate, and the particle size is 5-30 mu m;
the second isolating layer coating slurry comprises the following components: 3mg of H-HPC, 2.4mg of polyethylene glycol and absolute ethyl alcohol, wherein the solid content is 5wt%;
coating slurry on the film layer: opadry EZ coating powder (the model is Opadry EZ color, and the purchasing manufacturer is Shanghai Kalekang coating technology limited) and purified water, wherein the solid content is 20wt%;
the clopidogrel bisulfate aspirin tablet containing the second isolation coating layer is increased by 2.6 percent relative to the clopidogrel bisulfate aspirin tablet, and the film coating is increased by 5.4 percent relative to the clopidogrel bisulfate aspirin tablet containing the second isolation coating layer
The tablet weight of the clopidogrel sulfate aspirin tablet is 0.266 g/tablet.
Example 9
Clopidogrel sulfate aspirin tablets were prepared according to the method of example 1, differing from example 1 only in that:
the aspirin tablet comprises the following components: 100mg of aspirin (the ratio of the particle size of 20-60 meshes is 80%), 7mg of starch and 802 mg of microcrystalline cellulose;
the enteric coating comprises the following components: triethyl citrate 1.4mg, talcum powder 8.2mg, pure water 50mg, equid L30D-5540mg, weight gain 15%;
the first isolating layer coating slurry comprises the following components: H-HPC3.4mg, polyethylene 4000.6mg, and 4wt% of water solution, the weight is increased by 2%;
the composition of the medicine solution is as follows: 4.5mg of H-HPC, 6.7mg of L-HPC, 0.12mg of vitamin E and 6000.0 mg of polyethylene glycol are dissolved in absolute ethanol solution, 98.0mg of micronized clopidogrel sulfate is added, and the solid content is 24wt%; micronization treatment of clopidogrel sulfate is obtained by micronization treatment of clopidogrel sulfate, and the particle size is 5-30 mu m;
the second isolating layer coating slurry comprises the following components: H-HPC2.7mg, talcum powder 2.7mg, absolute ethyl alcohol, solid content is 5wt%;
coating slurry on the film layer: opadry EZ coating powder (the model is Opadry EZ color, and the purchasing manufacturer is Shanghai Kalekang coating technology limited) and purified water, wherein the solid content is 20wt%;
the clopidogrel bisulfate aspirin tablet containing the second isolation coating layer is increased by 3.6 percent relative to the clopidogrel bisulfate aspirin tablet, and the film coating is increased by 3.4 percent relative to the clopidogrel bisulfate aspirin tablet containing the second isolation coating layer
The tablet weight of the clopidogrel sulfate aspirin tablet is 0.266 g/tablet.
Example 10
Clopidogrel sulfate aspirin tablets were prepared according to the method of example 1, differing from example 1 only in that:
the aspirin tablet comprises the following components: 100mg of aspirin (the ratio of the particle size of 20-60 meshes is 80%), 7mg of starch and 802 mg of microcrystalline cellulose;
the enteric coating comprises the following components: triethyl citrate 1.0mg, talcum powder 8.2mg, pure water 50mg, equid L30D-5540mg, coating weight gain 18%;
the first isolating layer coating slurry comprises the following components: 3.5 of H-HPC and 1mg of polyethylene glycol to prepare a 3wt% aqueous solution, and the coating weight is increased by 2.8%;
the composition of the medicine solution is as follows: 8mg of H-HPC, 13mg of L-HPC, 20mg of starch, 10mg of lactose, 0.12mg of vitamin E and 6000 12mg of polyethylene glycol are dissolved in an absolute ethanol solution, 98.0mg of micronized clopidogrel sulfate is added, and the solid content is 25wt%; micronization treatment of clopidogrel sulfate is obtained by micronization treatment of clopidogrel sulfate, and the particle size is 5-30 mu m;
the second isolating layer coating slurry comprises the following components: 3mg of H-HPC, 2.4mg of talcum powder and absolute ethyl alcohol, wherein the solid content is 3wt%;
coating slurry on the film layer: opadry EZ coating powder (the model is Opadry EZ color, and the purchasing manufacturer is Shanghai Kalekang coating technology Co., ltd)) and purified water, wherein the solid content is 18wt%;
the clopidogrel hydrogen sulfate aspirin tablet containing the second isolating coat layer is increased by 3.6 percent relative to the clopidogrel hydrogen sulfate aspirin tablet, and the film coat is increased by 3.4 percent relative to the clopidogrel hydrogen sulfate aspirin tablet containing the second isolating coat layer
The tablet weight of the clopidogrel sulfate aspirin tablet is 0.322 g/tablet.
Example 11:
clopidogrel sulfate aspirin tablets were prepared according to the method of example 10, differing from example 10 only in that:
replacing the colored Opadry EZ coating powder with Opadry EZ transparent coating powder, and purchasing Kalopanan coating technology Co., ltd.) and purified water, wherein the solid content is 8wt%; the weight gain of the film coating is 3.4%.
The tablet weight of the clopidogrel sulfate aspirin tablet is 0.322 g/tablet.
Comparative example 1
Clopidogrel sulfate aspirin tablets were prepared according to the method of example 10, differing from example 10 only in that: comparative example 1 was prepared by replacing the colored opadry EZ coating powder with HPMC coating solution with 15% solids.
Test experiments:
(1) Ease of swallowing test: the ease of swallowing of the clopidogrel sulfate aspirin tablets prepared in comparative example 1, example 10, and example 11 was compared by dynamic friction, and the test results are shown in fig. 1, from which it can be seen that the friction force was significantly reduced in the sample coated with the opadry EZ series product shown in fig. 1.
(2) Test of dissolution performance of clopidogrel and aspirin in clopidogrel sulfate aspirin tablets
Dissolution curve: the clopidogrel aspirin tablets (self-made) and clopidogrel aspirin sulfate tablets (reference, pionfine (china) investment limited) prepared in examples 1 to 8 were subjected to dissolution measurement by a method specified in the imported registration standard JX 20200034.
The dissolution rate is determined by a dissolution rate and release rate determination method (first method of 0931 in the four-part general rules of the 2020 edition of Chinese pharmacopoeia).
Dissolution conditions (1): 1000mL of an acid solution (2.0 g of sodium chloride, 7.0mL of hydrochloric acid and water were added to dissolve the sodium chloride, water was added to dilute the solution to 1000mL, and the pH of the solution was 1.2) was used as a dissolution medium, the rotation speed was 75 rpm, the operation was performed according to the method, and samples were taken at 30 and 120 minutes.
Dissolution conditions (2): 1000mL of phosphate buffer (pH6.8) (anhydrous potassium dihydrogen phosphate 3.401 disodium hydrogen phosphate 3.55g, dissolved and diluted with water to 1000 mL) at a rotation speed of 100 rpm for 90 minutes;
the dissolution test was carried out, and the dissolution results are shown in FIGS. 2 to 17. FIG. 2 is a clopidogrel dissolution curve of a clopidogrel sulfate aspirin tablet prepared in example 1 and a clopidogrel sulfate tablet, FIG. 3 is an aspirin dissolution curve of a clopidogrel sulfate aspirin tablet prepared in example 1 and an aspirin tablet, FIG. 4 is a clopidogrel dissolution curve of a clopidogrel sulfate aspirin tablet prepared in example 2 and a clopidogrel sulfate tablet, FIG. 5 is an aspirin dissolution curve of a clopidogrel sulfate aspirin tablet prepared in example 2 and an aspirin tablet, FIG. 6 is a clopidogrel dissolution curve of a clopidogrel sulfate aspirin tablet prepared in example 3 and a clopidogrel sulfate tablet, FIG. 7 is an aspirin dissolution curve of a clopidogrel sulfate aspirin tablet prepared in example 3 and an aspirin tablet, FIG. 8 is a clopidogrel sulfate aspirin tablet prepared in example 4 and a clopidogrel sulfate tablet, FIG. 9 is an aspirin dissolution curve of a clopidogrel sulfate aspirin tablet prepared in example 4 with an aspirin tablet, FIG. 10 is a clopidogrel dissolution curve of a clopidogrel sulfate aspirin tablet prepared in example 5 with a clopidogrel sulfate tablet, FIG. 11 is an aspirin dissolution curve of a clopidogrel sulfate aspirin tablet prepared in example 5 with an aspirin tablet, FIG. 12 is a clopidogrel dissolution curve of a clopidogrel sulfate aspirin tablet prepared in example 6 with a clopidogrel sulfate tablet, FIG. 13 is an aspirin dissolution curve of a clopidogrel sulfate aspirin tablet prepared in example 6 with an aspirin tablet, FIG. 14 is a clopidogrel sulfate aspirin tablet prepared in example 7 with a clopidogrel sulfate tablet, FIG. 15 is an aspirin dissolution curve of a clopidogrel sulfate aspirin tablet prepared in example 7 with an aspirin tablet, fig. 16 is a clopidogrel dissolution curve of a clopidogrel sulfate aspirin sheet prepared in example 8 and a clopidogrel sulfate sheet, fig. 17 is an aspirin dissolution curve of a clopidogrel sulfate aspirin sheet prepared in example 8 and an aspirin sheet, fig. 18 is a clopidogrel dissolution curve of a clopidogrel sulfate aspirin sheet prepared in example 9 and a clopidogrel sulfate sheet, fig. 19 is an aspirin dissolution curve of a clopidogrel sulfate aspirin sheet prepared in example 9 and an aspirin sheet, fig. 20 is a clopidogrel dissolution curve of a clopidogrel sulfate aspirin sheet prepared in example 10 and a clopidogrel sulfate sheet, and fig. 21 is an aspirin dissolution curve of a clopidogrel sulfate aspirin sheet prepared in example 10 and an aspirin sheet, and it can be seen from fig. 2 to 21 that clopidogrel sulfate reference sheets in the clopidogrel sulfate aspirin sheet prepared in the invention substantially coincide, and aspirin dissolution curves of the clopidogrel sulfate aspirin sheets and the aspirin sheets are similar, and the in-vitro dissolution of a self-made product is consistent with a reference preparation.
(3) The results of stability test of clopidogrel sulfate aspirin tablets prepared in examples 1 to 8 are shown in tables 1 to 8. The stability test method comprises the following steps: the relevant substance detection method specified in the imported registration standard JX20200034 is used for detection.
Table 1 stability test results of clopidogrel-related substances in clopidogrel sulfate aspirin tablets obtained in examples 1 to 8
Table 2 results of stability test of aspirin-related substances in clopidogrel sulfate aspirin tablets obtained in examples 1 to 8
As can be seen from tables 1-2, the quality of the self-preparation was comparable to that of the reference preparation.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and amendments can be made without departing from the principle of the present invention, and these modifications and amendments should also be considered as the protection scope of the present invention.
Claims (10)
1. The clopidogrel sulfate aspirin tablet is characterized by sequentially comprising an aspirin tablet core, an enteric coating layer, a first isolation coating layer, a clopidogrel sulfate upper medicine layer, a second isolation coating layer and a film coating layer from inside to outside, wherein the mass of the clopidogrel sulfate aspirin tablet is less than or equal to 0.35 g/tablet;
based on the mass percentage content of the clopidogrel hydrogen sulfate aspirin tablet of 100 percent,
the aspirin tablet comprises the following components: 25 to 50 percent of aspirin, 0.25 to 4.5 percent of microcrystalline cellulose and 0.25 to 2 percent of diluent;
the composition of the enteric coating layer comprises: 2.5 to 6 percent of enteric coating powder, 0.25 to 1.2 percent of triethyl citrate and 1.25 to 4.8 percent of opacifier;
the composition of the first release coating layer comprises: 0.5 to 8 percent of high-substituted hydroxypropyl cellulose;
the clopidogrel sulfate medicine-applying layer comprises the following components: 19 to 38 percent of clopidogrel sulfate, 0.5 to 5 percent of adhesive, 0.05 to 2 percent of antioxidant, 0.02 to 1 percent of polyethylene glycol and 1 to 5 percent of disintegrant; the amount of clopidogrel sulfate is calculated by clopidogrel;
the composition of the second release coating layer comprises: 0.5 to 8 percent of high-substituted hydroxypropyl cellulose;
the film coating layer comprises the following components: 3-8% of Opadry EZ coating powder.
2. The clopidogrel sulfate aspirin tablet of claim 1, wherein the enteric coating powder comprises one or more of a copolymer of methacrylic acid and ethyl acrylate, a copolymer of methacrylic acid and methyl methacrylate, and a copolymer of methacrylic acid and methyl methacrylate.
3. The clopidogrel sulfate aspirin tablet of claim 1, wherein the opacifier comprises one or more of talc, calcium carbonate, calcium sulfate, and iron oxide.
4. The clopidogrel sulfate aspirin tablet of claim 1, wherein the diluent comprises starch and/or lactose.
5. The process for preparing clopidogrel sulfate aspirin tablet according to any one of claims 1 to 4, characterized by comprising the steps of:
mixing the enteric coating powder, triethyl citrate, an opacifier and water to obtain an enteric coating layer component solution;
mixing clopidogrel sulfate, an adhesive, an antioxidant, polyethylene glycol, a disintegrating agent and an alcohol solvent to obtain a medicinal solution;
mixing high-substituted hydroxypropyl cellulose and water to obtain first isolation layer coating pulp;
mixing the high-substituted hydroxypropyl cellulose and an alcohol solvent to obtain second isolation layer coating slurry;
mixing the Opadry EZ coating powder with water to obtain film coating layer slurry;
mixing aspirin, microcrystalline cellulose and a diluent, and tabletting to obtain an aspirin tablet;
performing enteric coating on the aspirin tablet by using the enteric coating layer component solution to obtain an aspirin enteric tablet;
coating the aspirin enteric-coated tablet by using the first isolating layer coating slurry to obtain an aspirin isolating enteric-coated tablet;
the aspirin isolation enteric-coated tablet is coated with the medicine coating solution to obtain clopidogrel hydrogen sulfate aspirin tablets;
carrying out second isolation layer coating on the clopidogrel hydrogen sulfate aspirin tablets by using the second isolation layer coating pulp, and then carrying out film layer coating by using the film coating layer coating pulp to obtain the clopidogrel hydrogen sulfate aspirin tablets;
the enteric coating, the first isolating layer coating, the medicine applying, the second isolating layer coating and the film layer coating are all carried out in a coating pan.
6. The method of claim 5, wherein the parameters of the first barrier layer coating include: the spraying speed is 60-120 g/min, the rotating speed of a coating pan is 3-8 r/min, and the material temperature is 28-35 ℃.
7. The method of claim 5, wherein the parameters of the enteric coating include: the spraying speed is 60-120 g/min, the rotating speed of a coating pan is 3-8 r/min, and the material temperature is 28-35 ℃.
8. The preparation method according to claim 5, wherein the process parameters of the drug delivery comprise: the spraying speed of the medicine solution is 60-260 g/min, the rotating speed of a coating pot is 3-12 r/min, and the material temperature is 25-45 ℃.
9. The method of claim 5, wherein the process parameters of the second barrier layer coating and the film layer coating comprise: the spraying speed is independently 60-120 g/min, the rotating speed of the coating pan is independently 3-8 r/min, and the material temperature is independently 25-50 ℃.
10. Use of the clopidogrel aspirin tablet of any one of claims 1 to 4 or the clopidogrel aspirin tablet prepared by the preparation method of any one of claims 5 to 9 in the preparation of a medicament for treating cardiovascular and cerebrovascular diseases.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211606681.7A CN115770229A (en) | 2022-12-13 | 2022-12-13 | Clopidogrel sulfate aspirin tablet and preparation method and application thereof |
PCT/CN2023/092864 WO2024124785A1 (en) | 2022-12-13 | 2023-05-09 | Clopidogrel bisulfate and aspirin tablet, preparation method therefor, and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211606681.7A CN115770229A (en) | 2022-12-13 | 2022-12-13 | Clopidogrel sulfate aspirin tablet and preparation method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115770229A true CN115770229A (en) | 2023-03-10 |
Family
ID=85392220
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211606681.7A Pending CN115770229A (en) | 2022-12-13 | 2022-12-13 | Clopidogrel sulfate aspirin tablet and preparation method and application thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN115770229A (en) |
WO (1) | WO2024124785A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024124785A1 (en) * | 2022-12-13 | 2024-06-20 | 山东诺明康药物研究院有限公司 | Clopidogrel bisulfate and aspirin tablet, preparation method therefor, and use thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102813664A (en) * | 2011-06-12 | 2012-12-12 | 王定豪 | Oral enteric preparation containing Grel drugs and aspirin |
WO2013065936A1 (en) * | 2011-11-02 | 2013-05-10 | 한국유나이티드제약 주식회사 | Complex agent containing clopidogrel and aspirin |
WO2013133620A1 (en) * | 2012-03-09 | 2013-09-12 | Yuhan Corporation | Pharmaceutical composition comprising clopidogrel and aspirin and process for preparing the same |
WO2016195153A1 (en) * | 2015-05-29 | 2016-12-08 | 한국유나이티드제약 주식회사 | Pharmaceutical composite preparation |
CN109288805A (en) * | 2018-11-21 | 2019-02-01 | 北京汇诚瑞祥医药技术有限公司 | A kind of compound aspirin bisulfate clopidogrel clad sheet and preparation method |
CN112587495A (en) * | 2020-12-14 | 2021-04-02 | 乐普药业股份有限公司 | Aspirin and clopidogrel hydrogen sulfate compound preparation and preparation method thereof |
CN115212180A (en) * | 2022-09-03 | 2022-10-21 | 深圳市信宜特科技有限公司 | Compound preparation of aspirin and clopidogrel hydrogen sulfate and preparation method thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015015062A1 (en) * | 2013-08-02 | 2015-02-05 | Sanofi | Pharmaceutical tablet comprising acetylsalicylic acid and clopidogrel |
WO2017160101A1 (en) * | 2016-03-16 | 2017-09-21 | 한국유나이티드제약 주식회사 | Composite preparation containing clopidogrel and aspirin |
CN115770229A (en) * | 2022-12-13 | 2023-03-10 | 山东诺明康药物研究院有限公司 | Clopidogrel sulfate aspirin tablet and preparation method and application thereof |
-
2022
- 2022-12-13 CN CN202211606681.7A patent/CN115770229A/en active Pending
-
2023
- 2023-05-09 WO PCT/CN2023/092864 patent/WO2024124785A1/en unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102813664A (en) * | 2011-06-12 | 2012-12-12 | 王定豪 | Oral enteric preparation containing Grel drugs and aspirin |
WO2013065936A1 (en) * | 2011-11-02 | 2013-05-10 | 한국유나이티드제약 주식회사 | Complex agent containing clopidogrel and aspirin |
WO2013133620A1 (en) * | 2012-03-09 | 2013-09-12 | Yuhan Corporation | Pharmaceutical composition comprising clopidogrel and aspirin and process for preparing the same |
WO2016195153A1 (en) * | 2015-05-29 | 2016-12-08 | 한국유나이티드제약 주식회사 | Pharmaceutical composite preparation |
CN109288805A (en) * | 2018-11-21 | 2019-02-01 | 北京汇诚瑞祥医药技术有限公司 | A kind of compound aspirin bisulfate clopidogrel clad sheet and preparation method |
CN112587495A (en) * | 2020-12-14 | 2021-04-02 | 乐普药业股份有限公司 | Aspirin and clopidogrel hydrogen sulfate compound preparation and preparation method thereof |
CN115212180A (en) * | 2022-09-03 | 2022-10-21 | 深圳市信宜特科技有限公司 | Compound preparation of aspirin and clopidogrel hydrogen sulfate and preparation method thereof |
Non-Patent Citations (1)
Title |
---|
制药在线: "欧巴代®EZ易吞服薄膜包衣***", pages 1, Retrieved from the Internet <URL:https://www.cphi.cn/Products/show-125933.html> * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024124785A1 (en) * | 2022-12-13 | 2024-06-20 | 山东诺明康药物研究院有限公司 | Clopidogrel bisulfate and aspirin tablet, preparation method therefor, and use thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2024124785A1 (en) | 2024-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1738754B1 (en) | Solid pharmaceutical preparation | |
CN1407894A (en) | Pharmaceutical composition | |
TWI590835B (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
EP1561472B2 (en) | Solid preparation | |
JP7395653B2 (en) | Tablets containing ferric citrate | |
KR20160054216A (en) | Pharmaceutical tablet comprising Choline Alphoscerate and method for manufacturing the same | |
CN115770229A (en) | Clopidogrel sulfate aspirin tablet and preparation method and application thereof | |
CN104997748B (en) | A kind of Nifedipine slow release tablet and its preparation technology for treating hypertension emergency | |
CN112587495A (en) | Aspirin and clopidogrel hydrogen sulfate compound preparation and preparation method thereof | |
WO2014040548A1 (en) | Metoprolol sustained-release drug and preparation method therefor | |
CN107998097B (en) | A kind of tablet and preparation method thereof containing olmesartan medoxomil | |
CN112451531A (en) | Aspirin and rivaroxaban compound preparation and preparation method thereof | |
US20070160670A1 (en) | Compression-coated tablets and manufacture thereof | |
US10420764B2 (en) | Pharmaceutical formulation of N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-YL]-4-[(3R,5S)-3 ,5-dimethylpiperazin-1-YL] benzamide | |
RU2727721C2 (en) | Sustained-release pharmaceutical composition containing rivastigmine | |
CN114432254A (en) | Nifedipine controlled release tablet | |
CN114146089A (en) | Pharmaceutical composition containing efavirenz, tenofovir and emtricitabine | |
CN105193757A (en) | Metoprolol sustained-release composition and preparation method thereof | |
CA2589200A1 (en) | Formulations of pyridoxal -5'-phosphate and methods of preparation | |
CN109806234A (en) | A kind of preparation method of proton pump inhibitor enteric label | |
CN116159033B (en) | Amlodipine benazepril solid preparation and preparation process thereof | |
CN114209675B (en) | Clopidogrel hydrogen sulfate aspirin microchip capsule and preparation method thereof | |
CN110934872B (en) | Levohydroxyeugenol capsule and preparation method thereof | |
CN109568281B (en) | Sulfasalazine tablet and preparation method thereof | |
CN118078768A (en) | Amlodipine atorvastatin calcium tablet and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |